Kuros Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
Kuros Biosciences has a total shareholder equity of CHF76.7M and total debt of CHF0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CHF110.0M and CHF33.3M respectively. Kuros Biosciences's EBIT is CHF3.9M making its interest coverage ratio 0.7. It has cash and short-term investments of CHF18.4M.
Key information
0%
Debt to equity ratio
CHF 0
Debt
| Interest coverage ratio | 0.7x |
| Cash | CHF 18.44m |
| Equity | CHF 76.65m |
| Total liabilities | CHF 33.32m |
| Total assets | CHF 109.97m |
Recent financial health updates
We're Not Worried About Kuros Biosciences' (VTX:KURN) Cash Burn
Mar 07
Kuros Biosciences (VTX:KURN) Is In A Strong Position To Grow Its Business
Nov 28We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Jul 16Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth
Dec 17We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Sep 17Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation
May 03Recent updates
Kuros Biosciences AG's (VTX:KURN) Sole Analyst Just Made A Notable Upgrade To Their Forecasts
Oct 18Kuros Biosciences AG's (VTX:KURN) P/S Is On The Mark
Oct 02Kuros Biosciences AG (VTX:KURN) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected
Apr 29We're Not Worried About Kuros Biosciences' (VTX:KURN) Cash Burn
Mar 07Kuros Biosciences AG's (VTX:KURN) 27% Share Price Plunge Could Signal Some Risk
Dec 13Kuros Biosciences (VTX:KURN) Is In A Strong Position To Grow Its Business
Nov 28Kuros Biosciences AG's (VTX:KURN) Shares Climb 30% But Its Business Is Yet to Catch Up
Oct 24Market Participants Recognise Kuros Biosciences AG's (VTX:KURN) Revenues Pushing Shares 37% Higher
Aug 22We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Jul 16Kuros Biosciences AG (VTX:KURN) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
May 30Why Investors Shouldn't Be Surprised By Kuros Biosciences AG's (VTX:KURN) 35% Share Price Surge
Apr 11Some Confidence Is Lacking In Kuros Biosciences AG (VTX:KURN) As Shares Slide 29%
Jan 03Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth
Dec 17We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Sep 17Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues
Jun 28Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation
May 03Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth
Jun 11Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now
Apr 12Reflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years
Mar 02What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay
Nov 17
Financial Position Analysis
Short Term Liabilities: KURN's short term assets (CHF60.7M) exceed its short term liabilities (CHF27.0M).
Long Term Liabilities: KURN's short term assets (CHF60.7M) exceed its long term liabilities (CHF6.3M).
Debt to Equity History and Analysis
Debt Level: KURN is debt free.
Reducing Debt: KURN has no debt compared to 5 years ago when its debt to equity ratio was 0.1%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KURN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if KURN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/07 00:19 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kuros Biosciences AG is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Volker Bosse | Baader Helvea Equity Research |
| Thomas Meyer | Baader Helvea Equity Research |